Carta al Editor
Replica a la carta al editor titulada: «Efectividad y seguridad de la eritropoyetina alfa en el paciente (ortopédico) mayor de 65 años»
Reply to the letter to the editor entitled: «Effectiveness and safety of erythropoietin alpha in the patient (orthopaedic) over 65 years»
Leído
1464
Vecesse ha leído el artículo
339
Total PDF
1125
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 8 | 3 | 11 |
| 2025 11 | 18 | 22 | 40 |
| 2025 10 | 20 | 11 | 31 |
| 2025 9 | 13 | 9 | 22 |
| 2025 8 | 11 | 9 | 20 |
| 2025 7 | 14 | 9 | 23 |
| 2025 6 | 22 | 6 | 28 |
| 2025 5 | 11 | 2 | 13 |
| 2025 4 | 17 | 2 | 19 |
| 2025 3 | 20 | 2 | 22 |
| 2025 2 | 5 | 3 | 8 |
| 2025 1 | 11 | 5 | 16 |
| 2024 12 | 11 | 1 | 12 |
| 2024 11 | 9 | 3 | 12 |
| 2024 10 | 9 | 3 | 12 |
| 2024 9 | 8 | 2 | 10 |
| 2024 8 | 11 | 5 | 16 |
| 2024 7 | 15 | 5 | 20 |
| 2024 6 | 15 | 1 | 16 |
| 2024 5 | 15 | 5 | 20 |
| 2024 4 | 9 | 2 | 11 |
| 2024 3 | 14 | 9 | 23 |
| 2024 2 | 12 | 5 | 17 |
| 2024 1 | 13 | 2 | 15 |
| 2023 12 | 11 | 3 | 14 |
| 2023 11 | 12 | 3 | 15 |
| 2023 10 | 19 | 7 | 26 |
| 2023 9 | 12 | 7 | 19 |
| 2023 8 | 10 | 6 | 16 |
| 2023 7 | 11 | 4 | 15 |
| 2023 6 | 10 | 5 | 15 |
| 2023 5 | 14 | 3 | 17 |
| 2023 4 | 22 | 1 | 23 |
| 2023 3 | 25 | 7 | 32 |
| 2023 2 | 14 | 4 | 18 |
| 2022 1 | 8 | 2 | 10 |
| 2022 12 | 14 | 9 | 23 |
| 2022 11 | 23 | 11 | 34 |
| 2022 10 | 16 | 8 | 24 |
| 2022 9 | 20 | 8 | 28 |
| 2022 8 | 23 | 5 | 28 |
| 2022 7 | 18 | 7 | 25 |
| 2022 6 | 21 | 9 | 30 |
| 2022 5 | 27 | 7 | 34 |
| 2022 4 | 56 | 12 | 68 |
| 2022 3 | 53 | 9 | 62 |
| 2022 2 | 54 | 7 | 61 |
| 2021 1 | 35 | 4 | 39 |
| 2021 12 | 41 | 7 | 48 |
| 2021 11 | 35 | 17 | 52 |
| 2021 10 | 46 | 7 | 53 |
| 2021 9 | 35 | 7 | 42 |
| 2021 8 | 9 | 8 | 17 |
| 2021 7 | 11 | 6 | 17 |
| 2020 9 | 2 | 1 | 3 |
| 2020 7 | 1 | 0 | 1 |
| 2020 6 | 2 | 0 | 2 |
| 2020 5 | 75 | 2 | 77 |
| 2020 1 | 1 | 0 | 1 |
| 2019 11 | 2 | 2 | 4 |
| 2019 9 | 4 | 2 | 6 |
| 2019 8 | 12 | 4 | 16 |
| 2019 7 | 9 | 0 | 9 |
| 2019 6 | 1 | 0 | 1 |
| 2019 4 | 0 | 2 | 2 |
Mostrar todo
